Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. The Company’s lead program, solabegron, is a highly potent and selective beta-3 adrenoceptor agonist that is being developed for overactive bladder (OAB). OAB is a condition that affects the quality of life for more than 80 million people worldwide − a number that will continue to grow as the population ages.
